newsfilter
← Latest News
GlobeNewswire·

Alector Reports Second Quarter 2025 Financial Results and Provides Business Update

On track to report topline data by mid-Q4 2025 from the pivotal INFRONT-3 Phase 3 clinical trial of latozinemab in FTD-GRN, a severe, rare form of dementia with no approved treatments Ongoing Phase 2 PROGRESS-AD trial